Research progress on the role of miRNA in drug resistance of pleural mesothelioma

WANG Xinmeng; LI Jinsong; LIN Yaru; TANG Ximin; PU Yuanqian; ZI Jiaji; XIONG Wei

doi:10.6039/j.issn.1001-0408.2024.22.22

您当前的位置：

首页 >

文章列表页 >

Research progress on the role of miRNA in drug resistance of pleural mesothelioma

更新时间：2024-11-26

- Research progress on the role of miRNA in drug resistance of pleural mesothelioma
- ZHONGGUO YAOFANG Vol. 35, Issue 22, Pages: 2832-2836(2024)
- 作者机构：
  
  1.大理大学基础医学院，云南大理　671000
  2.云南省高校临床生物化学检验重点实验室，云南大理　671000
  3.云南省昆虫生物医药研发重点实验室，云南大理　671000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.22.22
  CLC： R734.3;R969
- Published：30 November 2024，
  
  Received：04 April 2024，
  
  Revised：01 November 2024，
- 稿件说明：
移动端阅览
王心萌,李锦松,林亚茹等.miRNA在胸膜间皮瘤耐药中的作用研究进展 ^Δ[J].中国药房,2024,35(22):2832-2836.

WANG Xinmeng,LI Jinsong,LIN Yaru,et al.Research progress on the role of miRNA in drug resistance of pleural mesothelioma[J].ZHONGGUO YAOFANG,2024,35(22):2832-2836.
王心萌,李锦松,林亚茹等.miRNA在胸膜间皮瘤耐药中的作用研究进展 ^Δ[J].中国药房,2024,35(22):2832-2836. DOI： 10.6039/j.issn.1001-0408.2024.22.22.

WANG Xinmeng,LI Jinsong,LIN Yaru,et al.Research progress on the role of miRNA in drug resistance of pleural mesothelioma[J].ZHONGGUO YAOFANG,2024,35(22):2832-2836. DOI： 10.6039/j.issn.1001-0408.2024.22.22.

摘要

胸膜间皮瘤（PM）是来源于胸膜的一种罕见恶性肿瘤，大多数患者确诊时已为晚期，患者总体生存率低。微RNA（miRNA）作为肿瘤表观遗传修饰的关键调节因子，与PM耐药性之间有着彼此交错的互作网络。PM对化疗药物的耐药机制包括增加药物外流、减少药物摄取、增强DNA修复、改变药物靶点等；对靶向治疗药物的耐药机制则包括激活替代的信号通路、建立有利的肿瘤微环境、触发上皮-间充质转化等。miRNA在上述耐药机制中发挥了重要作用，部分miRNA可增强癌细胞的药物敏感性，但部分miRNA则具有增强耐药性的作用。鉴于这些关键调控作用，通过使用miRNA拮抗剂或miRNA模拟物靶向纠正耐药形成过程中内源性miRNA的表达失调，可能是逆转PM耐药一种有效的治疗策略。

Abstract

Pleural mesothelioma （PM） is a rare malignant tumor originating from the pleura. Most patients are already in the advanced stage at the time of diagnosis， resulting in a low overall survival rate. MicroRNA （miRNA）， as key regulators of tumor epigenetic modification， have an intertwined interactive network with PM drug resistance. The mechanisms of drug resistance in PM to chemotherapeutic drugs include increasing drug efflux， reducing drug intake， enhancing DNA repair， and altering drug targets. The mechanisms of resistance to targeted therapy drugs include activating alternative signaling pathways， establishing a favorable tumor microenvironment， and triggering epithelial-mesenchymal transition. MiRNA plays a key part in the aforementioned resistance mechanisms， with some miRNAs promoting the drug sensitivity of cancer cells， while others contribute to increased drug resistance. In light of these key regulatory functions， targeting the dysregulated expression of endogenous miRNAs in the process of resistance formation using miRNA antagonists or miRNA mimics may be an effective therapeutic strategy to reverse drug resistance in PM.

关键词

微RNA胸膜间皮瘤靶向治疗耐药

Keywords

pleural mesotheliomatargeted therapydrug resistance

references

YANG H T，XU D，SCHMID R A，et al. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma[J]. Ther Adv Med Oncol，2020，12：1758835920971421.

MANGIANTE L，ALCALA N，SEXTON-OATES A，et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity[J]. Nat Genet，2023，55（4）：607-618.

ABD-ELMAWLA M A，ABDEL MAGEED S S，AL-NOSHOKATY T M，et al. Melodic maestros：unraveling the role of miRNAs in the diagnosis，progression，and drug resistance of malignant pleural mesothelioma[J]. Pathol Res Pract，2023，250：154817.

SALMAN A T，SHAKER O，ELSHAER S S，et al. The expression profiling of serum miR-92a，miR-134 and miR-375 in acute ischemic stroke[J]. Future Sci OA，2022，8（10）：FSO829.

SATO Y，TOMITA M，SOGA T，et al. Upregulation of thymidylate synthase induces pemetrexed resistance in malignant pleural mesothelioma[J]. Front Pharmacol，2021，12：718675.

KENWORTHY R，BOSCO D B，DELIGIO J T，et al. Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression[J]. Cancer Biol Ther，2018，19（3）：181-187.

KARTHIKA C，SURESHKUMAR R，ZEHRAVI M，et al. Multidrug resistance of cancer cells and the vital role of P-glycoprotein[J]. Life，2022，12（6）：897.

CALLAGHAN R，LUK F，BEBAWY M. Inhibition of the multidrug resistance P-glycoprotein：time for a change of strategy?[J]. Drug Metab Dispos，2014，42（4）：623-631.

ARNESANO F，NATILE G. Interference between copper transport systems and platinum drugs[J]. Semin Cancer Biol，2021，76：173-188.

MALAKOTI F，TARGHAZEH N，ABADIFARD E，et al. DNA repair and damage pathways in mesothelioma deve-lopment and therapy[J]. Cancer Cell Int，2022，22（1）：176.

CIERNA Z，MISKOVSKA V，ROSKA J，et al. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours[J]. BMC Cancer，2020，20（1）：17.

BORCHERT S，WESSOLLY M，SCHMELLER J，et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro[J]. BMC Cancer，2019，19（1）：108.

MYLAVARAPU S，DAS A，ROY M. Role of BRCA mutations in the modulation of response to platinum therapy[J]. Front Oncol，2018，8：16.

SAWANT A，KOTHANDAPANI A，ZHITKOVICH A，et al. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links[J]. DNA Repair，2015，35：126-136.

BRONTE G，INCORVAIA L，RIZZO S，et al. The resistance related to targeted therapy in malignant pleural mesothelioma：why has not the target been hit yet?[J]. Crit Rev Oncol Hematol，2016，107：20-32.

CHU G J，LINTON A，KAO S，et al. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma[J]. Histopathology，2023，83（2）：202-210.

KANTETI R，RIEHM J J，DHANASINGH I，et al. PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma[J]. Sci Rep，2016，6：32992.

YANG H T，GAO Y Y，XU D，et al. MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma[J]. Cell Death Discov，2023，9（1）：55.

DUBOIS F，BAZILLE C，LEVALLET J，et al. Molecular alterations in malignant pleural mesothelioma：a hope for effective treatment by targeting YAP[J]. Target Oncol，2022，17（4）：407-431.

FU M Y，HU Y，LAN T X，et al. The Hippo signalling pathway and its implications in human health and diseases[J]. Signal Transduct Target Ther，2022，7（1）：376.

ANDO T，ARANG N，WANG Z Y，et al. EGFR regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1[J]. Commun Biol，2021，4（1）：1237.

CERSOSIMO F，BARBARINO M，LONARDI S，et al. Mesothelioma malignancy and the microenvironment：molecular mechanisms[J]. Cancers，2021，13（22）：5664.

PANZETTA V，MUSELLA I，FUSCO S，et al. ECM mechanoregulation in malignant pleural mesothelioma[J]. Front Bioeng Biotechnol，2022，10：797900.

ZHAO J，LIU B，LIU N，et al. The role of angiogenesis in malignant pleural effusion：from basic research to clinical application[J]. Am J Cancer Res，2022，12（11）：4879-4891.

GEMELLI M，CORTINOVIS D L，BAGGI A，et al. Immune checkpoint inhibitors in malignant pleural mesothelioma：a systematic review and meta-analysis[J]. Cancers，2022，14（24）：6063.

RAMUNDO V，ZANIRATO G，ALDIERI E. The epithelial-to-mesenchymal transition（EMT）in the deve-lopment and metastasis of malignant pleural mesothelioma[J]. Int J Mol Sci，2021，22（22）：12216.

DEBNATH P，HUIREM R S，DUTTA P，et al. Epithelial-mesenchymal transition and its transcription factors[J]. Biosci Rep，2022，42（1）：BSR20211754.

JOHNSON B，ZHUANG L，RATH E M，et al. Exploring microRNA and exosome involvement in malignant pleural mesothelioma drug response[J]. Cancers，2022，14（19）：4784.

GOTO A，TANAKA M，YOSHIDA M，et al. The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases[J]. PLoS One，2017，12（7）：e0181270.

ANOBILE D P，MONTENOVO G，PECORARO C，et al. Splicing deregulation，microRNA and Notch aberrations：fighting the three-headed dog to overcome drug resistance in malignant mesothelioma[J]. Expert Rev Clin Pharmacol，2022，15（3）：305-322.

LIU Q，FU H J，SUN F，et al. MiR-16 family induces cell cycle arrest by regulating multiple cell cycle genes[J]. Nucleic Acids Res，2008，36（16）：5391-5404.

LEZINA L，PURMESSUR N，ANTONOV A V，et al. MiR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress[J]. Cell Death Dis，2013，4（12）：e953.

SAFA，BAHROUDI Z，SHOOREI H，et al. MiR-1：a comprehensive review of its role in normal development and diverse disorders[J]. Biomed Pharmacother，2020，132：110903.

YUEN M，ZHUANG L，RATH E M，et al. The role of E-cadherin and microRNA on FAK inhibitor response in malignant pleural mesothelioma（MPM）[J]. Int J Mol Sci，2021，22（19）：10225.

TANG L，ZHOU L，WU S C，et al. MiR-125a-5p inhibits colorectal cancer cell epithelial-mesenchymal transition，invasion and migration by targeting TAZ[J]. Onco Targets Ther，2019，12：3481-3489.

ROMANOWICZ H，HOGENDORF P，MAJOS A，et al. Analysis of miR-143，miR-1，miR-210 and let-7e expression in colorectal cancer in relation to histopathological features[J]. Genes，2022，13（5）：875.

RUSSO G L，TESSARI A，CAPECE M，et al. Micro-RNAs for the diagnosis and management of malignant pleural mesothelioma：a literature review[J]. Front Oncol，2018，8：650.

FERRARI E，GANDELLINI P. Unveiling the ups and downs of miR-205 in physiology and cancer：transcriptional and post-transcriptional mechanisms[J]. Cell Death Dis，2020，11（11）：980.

YAMAMOTO K，SEIKE M，TAKEUCHI S，et al. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma[J]. Oncol Rep，2014，32（6）：2365-2372.

CIOCE M，RUTIGLIANO D，PUGLIELLI A，et al. Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of malignant pleural mesothelioma cells[J]. Cancer Drug Resist，2022，5（3）：814-828.

WANG Y，WANG M，YU P，et al. MicroRNA-126 modulates palmitate-induced migration in HUVECs by downregulating myosin light chain kinase via the ERK/MAPK pathway[J]. Front Bioeng Biotechnol，2020，8：913.

SUDHANVA M S，HARIHARASUDHAN G，JUN S，et al. MicroRNA-145 impairs classical non-homologous end-joining in response to ionizing radiation-induced DNA double-strand breaks via targeting DNA-PKcs[J]. Cells，2022，11（9）：1509.

MOODY H L，LIND M J，MAHER S G. MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma[J]. Mol Ther Nucleic Acids，2017，8：317-329.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on the role of resveratrol against breast cancer

Regulatory effect of autophagy on the resistance of human liver cancer cell Huh7 to lenvatinib

Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells

临床药师参与1例多重耐药芳香黄杆菌致骨组织感染患者治疗并文献复习

我院2008－2012年抗感染药物应用及细菌耐药趋势分析Δ

Related Author

BAI Guodong

YU Yangyang

XU Tao

LI Yan

DUAN Xufang

GAO Qingdong

DIAO Wenjing

CHEN Dahong

Related Institution

Dept. of Pharmacy， Jiamusi Hospital of TCM

Dept. of Pharmacy， Jiamusi Xiangyang District People’s Hospital

Dept. of Pharmacy， the Fourth Affiliated Hospital of Heilongjiang University of TCM

Preparation Room， Jiamusi Hospital of TCM

Dept. of Clinical Pharmacy， Shanghai General Hospital， Shanghai Jiao Tong University School of Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰